Clinical trial
Study of the Safety of VB6-845 in Patients With Advanced Solid Tumours of…
NCT00481936 · Sesen Bio, Inc., Industry · Terminated
Key facts
| NCT number | NCT00481936 |
|---|---|
| Title | Study of the Safety of VB6-845 in Patients With Advanced Solid Tumours of Epithelial Origin |
| Official title | A Phase I, Escalating Dose Study of VB6-845, a Recombinant Fusion Protein Targeting EpCAM, in Patients With Advanced Solid Tumours of Epithelial Origin |
| Lead sponsor | Sesen Bio, Inc., Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasms, Glandular and Epithelial |
| Intervention type | Drug |
| Interventions | VB6-845 |
| Enrollment | 15 |
| Start date | May 1, 2007 |
| Primary completion | Apr 1, 2008 |
| Completion | Apr 1, 2008 |
| First posted | Jun 4, 2007 |
| Last update posted | Mar 23, 2023 |
| Countries | Georgia, Russia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: